# To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy

> **NCT01322282** · PHASE1 · COMPLETED · sponsor: **McNeil AB** · enrollment: 36 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** Cetirizine
- **DRUG:** Cetirizine

## Key facts

- **NCT ID:** NCT01322282
- **Lead sponsor:** McNeil AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2012-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01322282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01322282, "To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01322282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*